查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715773

经皮贴片市场按产品类型、活性成分、递送系统、应用、最终用户和细分类型划分－2025-2030 年全球预测

Transdermal Patches Market by Product Type, Active Ingredient, Delivery System, Application, End User, Layer Type - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计 2024 年经皮贴片市场价值将达到 79.5 亿美元，到 2025 年将以 5.16% 的复合年增长率增长至 83.4 亿美元，到 2030 年将达到 107.5 亿美元。

主要市场统计数据
基准年2024年 79.5亿美元
预计2025年 83.4亿美元
预测年份 2030 107.5亿美元
复合年增长率（%） 5.16%

经皮吸收贴片市场处于药物传递的前沿，结合了先进的技术与以消费者为中心的优势。本报告探讨了市场驱动因素、技术创新和不断变化的消费者需求，以重塑药物输送方式。经皮吸收贴片可以长期、非侵入性、可控制且稳定地输送活性物质，提高患者的遵从性和舒适度。在个人化医疗和先进配方技术处于前沿的时代，经皮给药系统已成为管理慢性疾病和改善治疗效果的重要组成部分。经济压力、监管改革以及全球对以患者为中心的模式的关注都在共同重新定义市场重点。这项全面概述深入探讨了市场动态、竞争格局和区域差异，为决策者提供相关见解和可操作的数据。从贴片设计的创新到复杂的製造工艺，介绍为深入探索市场奠定了基调，在技术严谨性和巨大的商业性潜力之间取得了平衡。随后的讨论整合了新兴趋势和策略细分，以提供既具有广阔视角又具有详细技术细节的明智观点。

这种动态格局要求相关人员重新评估传统的经营模式，同时抓住先进材料和配方技术所提供的机会。以下部分对市场变化、细分洞察、区域差异化以及推动经皮贴片创新的主要企业说明了深入分析。

重新定义市场格局的转捩点

近年来，经皮贴片市场经历了彻底的变革，从根本上重新定义了市场格局。材料科学和药物配方的发展促进了贴剂的开发，从而提高了贴剂的渗透性、黏附性，并提供了更精确的控制释放曲线。新兴技术正在为智慧感测器和回馈机制的整合铺平道路，这些技术将彻底改变治疗方法的监测和调整方式。此外，多个地区的监管机构已经建立了强有力的框架，支持创新同时确保病患安全，加速了下一代贴片的市场推广。

技术进步、消费者偏好的不断变化以及全球向非侵入性治疗方法的转变，正在促使人们重新评估既定的通讯协定。医疗保健专业人士越来越提倡提供稳定药物动力学特征、减少不利事件可能性并提高患者依从性的治疗方法。医疗成本上涨和优化资源的需求等经济因素也使得经皮给药系统具有战略重要性。

在市场剧烈动盪的时期，企业正大力投资研发，并与学术机构和研究中心合作，进一步突破创新的界限。这些努力正逐步重塑竞争格局，并培育新的策略远见环境。因此，市场领导正在重新考虑产品系列和业务策略，以在快速变化的市场环境中保持领先地位。

揭示市场动态的关键细分洞察

详细的細項分析揭示了推动经皮贴片市场发展的不同方面。就产品类型而言，市场分为黏合剂贴片、基质贴片和微型储库贴片。自黏类型进一步分为多层和单层类型，这种区别突出了配方中的细微差别。类似地，也对多层和单层的基质贴片类别进行了评估，以深入了解材料的稳健性和释放动力学。这种分层细分可以更深入地了解设计特性和製造挑战，每个子集都解决了独特的治疗需求。

活性成分的细分揭示了可透过贴片输送的多种化合物。Buprenornhine、可乐定、Fentanyl、Lidocaine和尼古丁等关键成分是不断发展的产品系列的核心，每种成分都表现出独特的动态特性和临床指征。此外，输送系统的细分区分了控制释放和直接释放，这会影响剂量一致性和患者体验。值得注意的是，基于应用的细分涵盖了各种治疗领域，如心血管疾病、荷尔蒙补充疗法、神经系统疾病、疼痛管理、戒烟、伤口处理等。例如，对于心血管疾病，可乐定和硝酸异山梨酯贴片受到特别关注，而对于荷尔蒙补充疗法，有多种可供选择的方案，包括荷尔蒙组合贴片、雌激素贴片和黄体素贴片。此外，疼痛管理解决方案反映了进一步的细分，例如基于双氯芬酸钠的製剂、基于Fentanyl的製剂和基于Lidocaine的製剂。

最终用户洞察探索这些补丁最常部署在哪里。从门诊手术中心和居家医疗机构，到医院、诊所、专门研究实验室和学术机构，用途的多样性表明了这些解决方案的深远影响。最后，基于层类型（区分多层和单层配置）的分割提供了进一步的理解。这种复杂的细分矩阵使行业相关人员能够制定策略，以最佳方式渗透到每个细分市场，确保技术和消费群的创新始终处于市场发展的前沿。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 家庭医疗保健领域对实用、高效的药物管理解决方案的需求日益增长
      • 慢性病的增加催生了对替代性疼痛管理解决方案的需求
      • 新技术进步提高经皮贴片的有效性和便利性
    • 限制因素
      • 影响经皮贴片功效和安全性的生物相容性问题。
    • 机会
      • 将物联网技术整合到智慧经皮贴片中，实现即时健康监测
      • 个人化医疗的快速发展产生了对可客製化经皮吸收贴片解决方案的需求。
    • 任务
      • 解决经皮吸收贴片产业的智慧财产权和专利到期威胁
  • 市场区隔分析
    • 产品类型：多层药物贴片的渗透性大大提高，可容纳复杂的药物组合。
    • 最终用户：医院和诊所对广谱频谱的需求不断增长
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章经皮贴片市场（依产品类型）

  • 含药贴剂
    • 多层药物贴片
    • 单层药物内贴剂
  • 矩阵补丁
    • 多层矩阵
    • 单层矩阵
  • 微型储液罐贴片

经皮贴片市场（依活性成分）

  • Buprenornhine
  • 可乐定
  • Fentanyl
  • Lidocaine
  • 尼古丁

第 8 章经皮贴片市场（依递送系统）

  • 控释
  • 直接发布

经皮贴片市场（依应用）

  • 心血管疾病
    • 可乐定贴剂
    • 硝酸异山梨酯贴片
  • 荷尔蒙补充疗法
    • 联合荷尔蒙贴剂
    • 雌激素贴片
    • 黄体素贴剂
  • 神经系统疾病
  • 疼痛管理
    • 双氯芬酸钠
    • Fentanyl
    • Lidocaine碱
  • 禁止抽烟
  • 伤口处理

第 10 章经皮贴片市场（依最终用户划分）

  • 门诊手术中心
  • 居家照护环境
  • 医院和诊所
  • 研究和学术机构

经皮贴片市场（按层类型）

  • 多层
  • 单层

12.美洲经皮贴片市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区经皮贴片市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲经皮贴片市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • AbbVie Inc.
  • AdhexPharma SAS
  • Amneal Pharmaceuticals, Inc.
  • Bayer AG
  • BioNxt Solutions Inc.
  • Bliss GVS Pharma Ltd.
  • Boehringer Ingelheim International GmbH
  • Corium, Inc.
  • Corsair Pharma, Inc.
  • DifGen Pharmaceuticals LLC
  • Endo International plc
  • Gedeon Richter Plc
  • GlaxoSmithKline Plc
  • Icure Pharmaceutical Inc.
  • Johnson & Johnson Services, Inc.
  • LAVIPHARM GROUP HOLDING SA
  • Lohmann Therapie-Systeme AG
  • Luye Pharma Group Ltd
  • Medherant Limited
  • Nitto Denko Corporation
  • Novartis AG
  • Noven Pharmaceuticals, Inc. by Hisamitsu Pharmaceutical Co., Inc.
  • Nutriband Inc
  • Perrigo Company plc
  • ProSolus, Inc.
  • Purdue Pharma LP
  • Sparsha Pharma International Pvt Ltd
  • Teikoku Seiyaku Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Group
Product Code: MRR-FD3F12D540F6

The Transdermal Patches Market was valued at USD 7.95 billion in 2024 and is projected to grow to USD 8.34 billion in 2025, with a CAGR of 5.16%, reaching USD 10.75 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 7.95 billion
Estimated Year [2025] USD 8.34 billion
Forecast Year [2030] USD 10.75 billion
CAGR (%) 5.16%

The transdermal patches market represents a cutting-edge frontier in drug delivery, combining advanced technology with consumer-centric benefits. This report introduces key market drivers, technological innovations, and evolving consumer needs that are reshaping how medications are administered. Transdermal patches offer a non-invasive and controlled method of delivering actives steadily over a prolonged period, ensuring improved patient adherence and comfort. In an era where personalized medicine and advanced formulation technologies are at the forefront, the transdermal delivery system has emerged as an essential component in managing chronic conditions and enhancing therapeutic efficacy. Economic pressures, regulatory reforms, and a global emphasis on patient-centric models are all converging to redefine market priorities. This comprehensive overview delves into market dynamics, competitive landscapes, and geographic variations, ensuring that decision-makers are fully equipped with relevant insights and actionable data. From innovation in patch design to refined manufacturing processes, the introduction sets the tone for a detailed exploration of a market that balances technological rigor with significant commercial promise. The discussion that follows integrates emerging trends with strategic segmentation, offering an informed perspective that is both broad in scope and detailed in technical specificity.

In this dynamic landscape, stakeholders are called upon to re-evaluate traditional business models while embracing the opportunities brought forth by advanced materials and formulation techniques. The ensuing sections provide a thorough analysis of market shifts, segmentation insights, regional differentiators, and the key corporate players that are driving forward innovation in transdermal patch solutions.

Transformative Shifts Redefining the Market Landscape

Over recent years, the transdermal patches market has experienced transformative shifts that have fundamentally redefined its landscape. Advances in material science and drug formulation have facilitated the development of patches that offer enhanced permeability, improved adhesion, and more precise controlled release profiles. Emerging technologies have paved the way for the integration of smart sensors and feedback mechanisms, which are set to revolutionize how therapeutic regimens are monitored and adjusted over time. Regulatory bodies across multiple regions have also established robust frameworks that support innovation while ensuring patient safety, thereby opening doors for the accelerated introduction of next-generation patches into the market.

In addition to technological advancements, evolving consumer preferences and a global shift toward non-invasive treatment options have spurred a re-evaluation of established protocols. Healthcare professionals are increasingly advocating for treatments that provide steady pharmacokinetic profiles, reducing the likelihood of adverse events and improving patient compliance. Economic drivers, including rising healthcare costs and the need for resource optimization, have also reinforced the strategic importance of transdermal delivery systems, as they often reduce the need for frequent dosing and hospital visits.

This period of significant market disruption has prompted companies to invest heavily in R&D, forming collaborations with academic institutions and research centers to push the envelope of innovation further. These initiatives are gradually reshaping competitive dynamics and fostering an environment of renewed strategic foresight. Consequently, market leaders are rethinking product portfolios and operational strategies in a bid to stay ahead in a rapidly evolving market environment.

Key Segmentation Insights Illuminating Market Dynamics

Detailed segmentation analysis provides a clearer picture of the diverse dimensions propelling the transdermal patches market. When considering product type, the market is dissected into drug-in-adhesive patches, matrix patches, and micro-reservoir patches. The drug-in-adhesive segment further branches into multi-layer and single-layer variants, a distinction that underscores the nuanced approaches in formulation. Similarly, the matrix patches category is evaluated for multi-layer and single-layer differences, providing insight into material robustness and release kinetics. This layered segmentation offers a deeper understanding of design specifics and manufacturing challenges as each subset caters to unique therapeutic requirements.

The active ingredient segmentation sheds light on the variety of compounds being delivered via patches. Key ingredients such as buprenorphine, clonidine, fentanyl, lidocaine, and nicotine are central to the evolving product portfolio, each representing unique pharmacodynamic profiles and clinical indications. Further, the delivery system segmentation distinguishes between controlled release and direct release, which impact the dosage consistency and patient experience. Notably, application-based segmentation spans across various therapeutic areas including cardiovascular disorders, hormone replacement therapy, neurological conditions, pain management, smoking cessation, and wound management. For instance, within cardiovascular disorders, special focus is given to clonidine and isosorbide dinitrate patches, whereas hormone replacement therapy options are diversified into combination hormone, estrogen, and progestin patches. Pain management solutions also reflect further segmentation through diclofenac-based, fentanyl-based, and lidocaine-based formulations.

End user insights explore where these patches are most commonly deployed. From ambulatory surgical centers and homecare settings to hospitals, clinics, and specialized research and academic institutes, the diversity in usage underscores the extensive reach of these solutions. Finally, segmentation based on layer type - distinguishing multi-layer versus single-layer configurations - further refines our understanding. This intricate segmentation matrix provides industry players with the ability to tailor strategies for optimum penetration of each niche segment, ensuring that both technological and consumer-based innovations remain at the forefront of market development.

Based on Product Type, market is studied across Drug-In-Adhesive Patches, Matrix Patches, and Micro-Reservoir Patches. The Drug-In-Adhesive Patches is further studied across Multi-Layer Drug-In-Adhesive Patches and Single-Layer Drug-In-Adhesive Patches. The Matrix Patches is further studied across Multi-Layer Matrix and Single-Layer Matrix.

Based on Active Ingredient, market is studied across Buprenorphine, Clonidine, Fentanyl, Lidocaine, and Nicotine.

Based on Delivery System, market is studied across Controlled Release and Direct Release.

Based on Application, market is studied across Cardiovascular Disorders, Hormone Replacement Therapy, Neurological Conditions, Pain Management, Smoking Cessation, and Wound Management. The Cardiovascular Disorders is further studied across Clonidine Patches and Isosorbide Dinitrate Patches. The Hormone Replacement Therapy is further studied across Combination Hormone Patches, Estrogen Patches, and Progestin Patches. The Pain Management is further studied across Diclofenac-Based, Fentanyl-Based, and Lidocaine-Based.

Based on End User, market is studied across Ambulatory Surgical Centers, Homecare Settings, Hospitals & Clinics, and Research & Academic Institutes.

Based on Layer Type, market is studied across Multi-Layer and Single Layer.

Key Regional Insights Shaping the Global Market

Regional analysis reveals distinct market dynamics that vary significantly across different geographical landscapes. In the Americas, robust healthcare infrastructures combined with high consumer awareness drive demand for innovative and reliable transdermal solutions. Regions within this territory are characterized by strict regulatory standards that ensure product reliability and safety while encouraging technological advancements. Investors and market strategists continue to focus on growth prospects in this region due to its rapid adoption of non-invasive treatment modalities.

Across Europe, the Middle East, and Africa, a unique blend of mature healthcare systems and emerging market opportunities creates an environment ripe for innovation. European markets are leveraging established regulatory mechanisms to balance innovation with patient safety, while initiatives in the Middle East and Africa often display a growing demand for advanced therapeutics as both government and private sectors invest in modernizing healthcare infrastructure. The convergence of legacy systems and modern technology across these regions often results in tailored approaches to product development and market penetration.

In the Asia-Pacific region, dynamic economic developments, increasing disposable incomes, and rapid urbanization play a pivotal role in expanding market reach. Emerging healthcare demands, coupled with ongoing investments in research and development, have positioned the region as a significant hub for transdermal patch innovation. Overall, regional nuances are critical to understanding the broader market, as cultural, economic, and regulatory differences influence therapeutic adoption rates and shape strategic initiatives for market players around the globe.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Comprehensive Company Insights Driving Market Innovation

The competitive landscape of the transdermal patches market is defined by a cadre of innovative companies who are pushing the boundaries of research and development. Prominent industry players such as AbbVie Inc. and AdhexPharma SAS are at the forefront of integrating advanced materials and formulation technologies to produce next-generation patch solutions. Amneal Pharmaceuticals, Inc. and Bayer AG continue to contribute to market growth by focusing on patient-centric designs that enhance drug delivery efficiency and adherence. Start-ups and established entities alike, including BioNxt Solutions Inc. and Bliss GVS Pharma Ltd., are merging innovation with proven manufacturing techniques to maintain competitive advantages.

Large multinationals such as Boehringer Ingelheim International GmbH and Corium, Inc. have significantly influenced market practices by adopting strategic partnerships and prioritizing clinical efficacy. Other companies like Corsair Pharma, Inc. and DifGen Pharmaceuticals LLC bring specialized expertise into play, while Endo International plc, Gedeon Richter Plc, and GlaxoSmithKline Plc contribute to the evolution of clinical protocols through groundbreaking research. The vibrant competitive landscape is further enriched by players such as Icure Pharmaceutical Inc. and Johnson & Johnson Services, Inc., whose comprehensive product portfolios cater to diverse therapeutic needs. Companies including LAVIPHARM GROUP HOLDING S.A. and Lohmann Therapie-Systeme AG are well-regarded for their commitment to advancing transdermal technology. Additional market influencers like Luye Pharma Group Ltd, Medherant Limited, Nitto Denko Corporation, Novartis AG, and Noven Pharmaceuticals, Inc. by Hisamitsu Pharmaceutical Co., Inc. have also carved out significant market niches. The landscape is further expanded by innovators such as Nutriband Inc, Perrigo Company plc, ProSolus, Inc., Purdue Pharma L.P., Sparsha Pharma International Pvt Ltd, Teikoku Seiyaku Co., Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Group. Together, these companies drive market momentum by combining clinical expertise with dynamic innovation, pushing forward a market that continues to evolve at an unprecedented pace.

The report delves into recent significant developments in the Transdermal Patches Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AdhexPharma SAS, Amneal Pharmaceuticals, Inc., Bayer AG, BioNxt Solutions Inc., Bliss GVS Pharma Ltd., Boehringer Ingelheim International GmbH, Corium, Inc., Corsair Pharma, Inc., DifGen Pharmaceuticals LLC, Endo International plc, Gedeon Richter Plc, GlaxoSmithKline Plc, Icure Pharmaceutical Inc., Johnson & Johnson Services, Inc., LAVIPHARM GROUP HOLDING S.A., Lohmann Therapie-Systeme AG, Luye Pharma Group Ltd, Medherant Limited, Nitto Denko Corporation, Novartis AG, Noven Pharmaceuticals, Inc. by Hisamitsu Pharmaceutical Co., Inc., Nutriband Inc, Perrigo Company plc, ProSolus, Inc., Purdue Pharma L.P., Sparsha Pharma International Pvt Ltd, Teikoku Seiyaku Co., Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., and Zydus Group. Actionable Recommendations for Strategic Market Leadership

For industry leaders looking to secure a competitive edge in the transdermal patches market, several actionable strategies are recommended. First, investment in research and development is paramount. Leaders should focus on emerging technologies that enable enhanced drug delivery mechanisms and the integration of smart monitoring systems. This commitment to innovation will not only meet but exceed the growing demands for precision and efficacy in patient care. Collaborations with academic institutions and cross-disciplinary research teams can serve as a vital source of breakthrough ideas and facilitate faster time-to-market for novel products.

Furthermore, it is critical to adopt a market segmentation approach that is informed by detailed insights into product type, active ingredients, delivery systems, and application-specific requirements. Tailoring product offerings to meet the specific needs of diverse demographics and therapeutic areas will bolster market penetration. Strategic regional investments are also essential; understanding local regulatory environments and consumer behaviors across the Americas, Europe, the Middle East, Africa, and Asia-Pacific can help create targeted marketing strategies and streamlined supply chains.

Additionally, forging strategic partnerships with key opinion leaders, healthcare providers, and regulatory bodies will help in navigating evolving market conditions. Emphasizing sustainability and operational efficiency throughout the supply chain will further cement a company's position as a market leader. Ultimately, a forward-thinking approach, underpinned by continuous learning and agile adaptation to industry trends, will serve as the cornerstone for sustained success in this competitive and dynamic sector.

Conclusion: Summarizing Critical Market Insights

In summary, the transdermal patches market stands at the nexus of innovation and opportunity. This comprehensive analysis highlights the dynamic interplay between advanced formulation technologies, strategic segmentation, and evolving regulatory landscapes. By synthesizing key insights from product-type distinctions to geographic and operational dynamics, we gain a detailed understanding of how shifting consumer demands, technological advancements, and evolving healthcare models are reshaping the industry. The segmentation insights reveal intricate differences in product design, from drug-in-adhesive systems to matrix configurations, as well as the nuanced deployment of active ingredients such as buprenorphine, clonidine, fentanyl, lidocaine, and nicotine. The disaggregation into various delivery systems and specialized applications further emphasizes the market's depth. Regional assessments articulate how varying economic and regulatory environments in the Americas, Europe, the Middle East, Africa, and Asia-Pacific are determining localized market behavior.

As many companies continue to innovate, they foster competitive environments where clinical efficacy, patient-centric design, and sustainable practices are key drivers of success. This analysis not only offers clarity on where the market is headed but also provides strategic insights necessary for navigating its complexities. The conclusions drawn here serve as a valuable framework for industry stakeholders seeking long-term stability and growth in an evolving therapeutic landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand in the home healthcare sector for practical and efficient medication management solutions
      • 5.1.1.2. Rising prevalence of chronic diseases necessitating alternative pain management solutions
      • 5.1.1.3. New technological advancements improving the efficacy and convenience of transdermal patches
    • 5.1.2. Restraints
      • 5.1.2.1. Biocompatibility issues impacting the effectiveness and safety of transdermal patches
    • 5.1.3. Opportunities
      • 5.1.3.1. Integrating IoT technology into smart transdermal patches for real-time health monitoring
      • 5.1.3.2. Rapid growth in personalized medicine creates demand for customizable transdermal patch solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Tackling intellectual property and patent expiration threats in the transdermal patch industry
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type : Significant penetration of multi-layer drug-in-adhesive patches due to its ability to house complex medication combinations
    • 5.2.2. End User : Growing need of patches with a broad spectrum in hospitals & clinics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Transdermal Patches Market, by Product Type

  • 6.1. Introduction
  • 6.2. Drug-In-Adhesive Patches
    • 6.2.1. Multi-Layer Drug-In-Adhesive Patches
    • 6.2.2. Single-Layer Drug-In-Adhesive Patches
  • 6.3. Matrix Patches
    • 6.3.1. Multi-Layer Matrix
    • 6.3.2. Single-Layer Matrix
  • 6.4. Micro-Reservoir Patches

7. Transdermal Patches Market, by Active Ingredient

  • 7.1. Introduction
  • 7.2. Buprenorphine
  • 7.3. Clonidine
  • 7.4. Fentanyl
  • 7.5. Lidocaine
  • 7.6. Nicotine

8. Transdermal Patches Market, by Delivery System

  • 8.1. Introduction
  • 8.2. Controlled Release
  • 8.3. Direct Release

9. Transdermal Patches Market, by Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Disorders
    • 9.2.1. Clonidine Patches
    • 9.2.2. Isosorbide Dinitrate Patches
  • 9.3. Hormone Replacement Therapy
    • 9.3.1. Combination Hormone Patches
    • 9.3.2. Estrogen Patches
    • 9.3.3. Progestin Patches
  • 9.4. Neurological Conditions
  • 9.5. Pain Management
    • 9.5.1. Diclofenac-Based
    • 9.5.2. Fentanyl-Based
    • 9.5.3. Lidocaine-Based
  • 9.6. Smoking Cessation
  • 9.7. Wound Management

10. Transdermal Patches Market, by End User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Homecare Settings
  • 10.4. Hospitals & Clinics
  • 10.5. Research & Academic Institutes

11. Transdermal Patches Market, by Layer Type

  • 11.1. Introduction
  • 11.2. Multi-Layer
  • 11.3. Single Layer

12. Americas Transdermal Patches Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Transdermal Patches Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Transdermal Patches Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. China Grants approval for Sino Biopharm's first domestic rivastigmine transdermal patch for alzheimer's treatment
    • 15.3.2. Agile Therapeutics finalizes acquisition by Insud Pharma enhancing product portfolio
    • 15.3.3. Jolt Health Inc. to enhance treatment options with acquisition of HCQ transdermal patch technology
    • 15.3.4. Medherant and Bayer collaborate to innovate transdermal patch delivery for oral medicines
    • 15.3.5. DifGen Pharmaceuticals Launches A Second Product - Buprenorphine Transdermal System From Its U.S. Manufacturing Site Aveva Drug Delivery Systems; Expanding Its Portfolio Of Manufacturing & Marketing U.S. Made Transdermal Patches And Sublingual Films
    • 15.3.6. Luye Pharma Ltd Launches New Alzheimer's Treatment In The UK
    • 15.3.7. Corsair Pharma Announces USD 23 Million Series B Financing to Advance Clinical Trials in Pulmonary Arterial Hypertension
    • 15.3.8. Vaxess Raises USD 9 Million to Accelerate mRNA Vaccine Patch Development
    • 15.3.9. Almirall Acquires Rights To Distribute Alzheimer's Treatment In Spain For An Initial EUR 45 Million
    • 15.3.10. Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY in Multiple Markets Across Asia
    • 15.3.11. Dexmedetomidine Transdermal Patch Fast Tracked for Postop Pain Management
    • 15.3.12. LTS Completes its Entry into Large Molecule Drug Delivery with the Acquisition of the Sorrel Wearable Injection Device Business
    • 15.3.13. BioNxt Receives Approval for European Clinical Study of Transdermal Rotigotine Patch for Parkinson's Disease
    • 15.3.14. Bionxt Signs Clinical Study Agreement and Commences Manufacture of Clinical Samples for Study of Transdermal Rotigotine Patch for Parkinson's Disease
    • 15.3.15. LTS Lohmann Leads Investment in Needle-Free Delivery Specialist
    • 15.3.16. The Addition of Tesa Labtec GmbH Marks a Cornerstone in AdhexPharma's Growth Path
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. AdhexPharma SAS
  • 3. Amneal Pharmaceuticals, Inc.
  • 4. Bayer AG
  • 5. BioNxt Solutions Inc.
  • 6. Bliss GVS Pharma Ltd.
  • 7. Boehringer Ingelheim International GmbH
  • 8. Corium, Inc.
  • 9. Corsair Pharma, Inc.
  • 10. DifGen Pharmaceuticals LLC
  • 11. Endo International plc
  • 12. Gedeon Richter Plc
  • 13. GlaxoSmithKline Plc
  • 14. Icure Pharmaceutical Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. LAVIPHARM GROUP HOLDING S.A.
  • 17. Lohmann Therapie-Systeme AG
  • 18. Luye Pharma Group Ltd
  • 19. Medherant Limited
  • 20. Nitto Denko Corporation
  • 21. Novartis AG
  • 22. Noven Pharmaceuticals, Inc. by Hisamitsu Pharmaceutical Co., Inc.
  • 23. Nutriband Inc
  • 24. Perrigo Company plc
  • 25. ProSolus, Inc.
  • 26. Purdue Pharma L.P.
  • 27. Sparsha Pharma International Pvt Ltd
  • 28. Teikoku Seiyaku Co., Ltd.
  • 29. Teva Pharmaceutical Industries Ltd.
  • 30. Viatris Inc.
  • 31. Zydus Group

LIST OF FIGURES

  • FIGURE 1. TRANSDERMAL PATCHES MARKET MULTI-CURRENCY
  • FIGURE 2. TRANSDERMAL PATCHES MARKET MULTI-LANGUAGE
  • FIGURE 3. TRANSDERMAL PATCHES MARKET RESEARCH PROCESS
  • FIGURE 4. TRANSDERMAL PATCHES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. TRANSDERMAL PATCHES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. TRANSDERMAL PATCHES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TRANSDERMAL PATCHES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TRANSDERMAL PATCHES MARKET DYNAMICS
  • TABLE 7. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY MULTI-LAYER DRUG-IN-ADHESIVE PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY SINGLE-LAYER DRUG-IN-ADHESIVE PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY MULTI-LAYER MATRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY SINGLE-LAYER MATRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY MICRO-RESERVOIR PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY BUPRENORPHINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY CLONIDINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY FENTANYL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY LIDOCAINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY NICOTINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY CONTROLLED RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY DIRECT RELEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY CLONIDINE PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY ISOSORBIDE DINITRATE PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY COMBINATION HORMONE PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY ESTROGEN PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY PROGESTIN PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY NEUROLOGICAL CONDITIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY DICLOFENAC-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY FENTANYL-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY LIDOCAINE-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY SMOKING CESSATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY WOUND MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY RESEARCH & ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY MULTI-LAYER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL TRANSDERMAL PATCHES MARKET SIZE, BY SINGLE LAYER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES TRANSDERMAL PATCHES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 136. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 140. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 145. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 146. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 147. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 148. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 150. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 152. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 156. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 157. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 158. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 159. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 161. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 162. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 163. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 164. INDIA TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 167. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 168. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 169. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 170. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 172. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 174. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. INDONESIA TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 178. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 179. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 180. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 181. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 183. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 184. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 185. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 186. JAPAN TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 189. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 190. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 191. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 192. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 194. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 196. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. MALAYSIA TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 200. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 202. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 205. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 207. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. PHILIPPINES TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 211. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 212. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 213. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 214. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 215. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 216. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 218. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 219. SINGAPORE TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 222. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 224. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 225. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 227. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 229. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. SOUTH KOREA TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 233. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 234. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 235. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 236. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 238. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 239. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 240. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 241. TAIWAN TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 243. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 244. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 245. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 246. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 247. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 248. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 249. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 250. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 251. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. THAILAND TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 255. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 256. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 257. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 258. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 260. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 261. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 262. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. VIETNAM TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA TRANSDERMAL PATCHES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 276. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 278. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 279. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 280. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 281. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 283. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 284. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 285. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 286. DENMARK TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 288. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 289. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 290. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 291. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 292. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 293. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 294. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 295. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 296. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 297. EGYPT TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 300. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 301. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 302. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 303. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 304. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 305. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 306. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 307. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 308. FINLAND TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 309. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 311. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 312. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 313. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 314. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 315. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 316. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 317. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 318. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. FRANCE TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHES, 2018-2030 (USD MILLION)
  • TABLE 322. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY MATRIX PATCHES, 2018-2030 (USD MILLION)
  • TABLE 323. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2030 (USD MILLION)
  • TABLE 324. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY DELIVERY SYSTEM, 2018-2030 (USD MILLION)
  • TABLE 325. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 326. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY CARDIOVASCULAR DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 327. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY HORMONE REPLACEMENT THERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY PAIN MANAGEMENT, 2018-2030 (USD MILLION)
  • TABLE 329. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 330. GERMANY TRANSDERMAL PATCHES MARKET SIZE, BY LAYER TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. ISRAEL TRANSDERMAL PATCHES MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. ISRAEL TRANSDERMAL PATCHES MARKET SIZE, BY DRUG-IN-ADHESIVE PATCHE